https://www.selleckchem.com/Androgen-Receptor.html
This represents an opportunity to improve the safety profile of this highly effective regimen. Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) have become a cornerstone of therapy in the management ovarian cancer and other cancers. PARPi are associated with significant toxicities and management strategies are primarily founded on clinical trial experience. This study aimed to provide an evaluation of patients receiving PARPi therapy within an academic health-system. A retrospective, observational study of adult patients
Like
Comment
Share
